FIG. 2.
Fold change in the BVM EC50 for the 31 patient-derived isolates compared to the EC50 for the wild-type control stratified according to antiretroviral therapy status (A) or the presence of protease inhibitor resistance (PI-R) (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.